'Healthcare is grossly under-engineered,' says Johns Hopkins' Pronovost (podcast)

January 18, 2013 by Arezu Sarvestani

Johns Hopkins patient safety expert Peter Pronovost on medical errors, medical device data and the role medtech must accept in preventing needless deaths.

Peter Pronovost of Johns Hopkins Medical

Healthcare providers are looking to medical devices to play a new role in hospital care, providing a whole-patient view of health through technologies that talk to each other and help clinicians make decisions about treatment.

Dr. Peter Pronovost, a critical care physician and anesthesiologist as well as Johns Hopkins Medicine senior vice president for patient safety & quality, told MassDevice.com that healthcare has yet to make the kind of progress innovative technologies have brought to other industries.


MassDevice.com podcast

Click to play

"Ironically, healthcare has invested significantly in technology, but it's the only industry for which technology hasn't helped productivity or safety," Pronovost told us. "In part, that's because we've invested in individual devices, but we haven't looked at integrating them as systems."

Sign up to get our free newsletters delivered right to your inbox.

Our conversation with Pronovost followed his appearance at the Patient Safety, Science & Technology Summit in Laguna Beach, Calif., last Sunday and Monday, where he and other healthcare stakeholders asked medical device makers to pledge to open up their devices to share data and develop interoperability around patient care and monitoring.

Comments

Features

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.